Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
2 July 2018

Oryzon to present at upcoming international conferences

25 June 2018

ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

1 June 2018

Oryzon to present at upcoming international conferences

30 May 2018

Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day

29 May 2018

ORYZON receives approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

14 May 2018

ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

9 May 2018

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018

8 May 2018

ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

3 May 2018

ORYZON covered for the first time by a US investment bank: ROTH Capital Partners

29-31 May 2018

Foro MEDCAP2018

Madrid Stock Exchange Palace

Madrid

Spain

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Current page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel